Pennsylvania will receive $8.3 million from the $465 million Mylan has agreed to pay to settle allegations that it overcharged Medicaid for the EpiPen, Pennsylvania Attorney General Josh Shapiro said Friday.
The generic drug maker announced Thursday that it had settled with the U.S. Justice Department, which alleged Mylan had misclassified the emergency allergy shot as a generic product. That allowed Mylan to pay lower rebates to the Medicaid program and resulted in states paying more for the product.
Drug companies are responsible for ensuring that their products are correctly classified.
Mylan disclosed a tentative settlement in October. On Thursday, the drug maker said it will reclassify the EipPen as a brand name drug and pay higher rebates under Medicaid’s drug rebate program, retroactive to April 1, 2017.
Federal investigators were tipped off to the misclassification by Sanofi, a rival drug company that filed a complaint against Mylan on behalf of the government last year. Sanofi will receive $38.7 million from the settlement as well as a share of what states recover.
Mylan did not admit any wrongdoing as part of the settlement.
“Mylan knowingly profited from its misclassification of EpiPen, scamming Pennsylvanians and putting their profit above people’s health and safety,” Mr. Shapiro said.
The $8.3 million Pennsylvania is receiving will go into state accounts that fund Medicaid in Pennsylvania.
Mylan is incorporated in the Netherlands but is run from executive offices in Cecil.
Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.